MGTX Insider Trading

Insider Ownership Percentage: 8.40%
Insider Buying (Last 12 Months): $5,000,000.00
Insider Selling (Last 12 Months): $382,838.33

MeiraGTx Insider Trading History Chart

This chart shows the insider buying and selling history at MeiraGTx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$383ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

MeiraGTx Share Price & Price History

Current Price: $6.78
Price Change: Price Decrease of -0.55 (-7.50%)
As of 03/31/2025 05:00 PM ET

This chart shows the closing price history over time for MGTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$7.33Closing price on 03/30/25:

MeiraGTx Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for MeiraGTx (NASDAQ:MGTX)

67.48% of MeiraGTx stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MGTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$98Mbought$8.76MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50M$0$50MTotal InflowsTotal Outflows
MeiraGTx logo
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Read More on MeiraGTx

Today's Range

Now: $6.78
Low: $6.63
High: $7.17

50 Day Range

MA: $6.83
Low: $6.04
High: $8.25

52 Week Range

Now: $6.78
Low: $3.85
High: $8.75

Volume

1,030,813 shs

Average Volume

286,946 shs

Market Capitalization

$534.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23

Who are the company insiders with the largest holdings of MeiraGTx?

MeiraGTx's top insider investors include:
  1. Perceptive Advisors Llc (Director)
  2. Alexandria Forbes (CEO)
  3. Richard Giroux (CFO)
Learn More about top insider investors at MeiraGTx.

Who are the major institutional investors of MeiraGTx?

MeiraGTx's top institutional investors include:
  1. Sanofi — 15.61%
  2. Adage Capital Partners GP L.L.C. — 6.44%
  3. Prosight Management LP — 5.62%
  4. 683 Capital Management LLC — 3.09%
  5. Woodline Partners LP — 1.96%
  6. Royce & Associates LP — 0.78%
Learn More about top institutional investors of MeiraGTx stock.

Which major investors are selling MeiraGTx stock?

During the last quarter, MGTX stock was sold by these institutional investors:
  1. Prosight Management LP
  2. Adage Capital Partners GP L.L.C.
  3. Royce & Associates LP
  4. 683 Capital Management LLC
  5. Russell Investments Group Ltd.
  6. Dimensional Fund Advisors LP
  7. Los Angeles Capital Management LLC
  8. Millennium Management LLC
During the previous year, company insiders that have sold MeiraGTx company stock include:
  1. Perceptive Advisors Llc (Director)
  2. Alexandria Forbes (CEO)
Learn More investors selling MeiraGTx stock.

Which major investors are buying MeiraGTx stock?

In the previous quarter, MGTX stock was purchased by institutional investors including:
  1. Sanofi
  2. Woodline Partners LP
  3. Long Focus Capital Management LLC
  4. Knott David M Jr
  5. Geode Capital Management LLC
  6. Janney Montgomery Scott LLC
  7. Nuveen Asset Management LLC
  8. Northern Trust Corp